Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health, Illumina Settle Patent Suit, Renew Long-Term Commercial Partnership

NEW YORK – Guardant Health on Tuesday said it has resolved the lawsuit that Illumina had filed against it last year alleging patent infringement, trade secret misappropriation, and breach of contract.

The companies have agreed to make a joint request to dismiss with prejudice the pending litigation between them, including any allegations related to the subject intellectual property.

In the suit, filed in March 2022, Illumina had alleged that Guardant co-CEOs Helmy Eltoukhy and AmirAli Talasaz had applied for patents now assigned to Guardant based on technology they developed while they were still employed by Illumina.

In addition to settling the suit, Guardant said the companies have signed a three-year agreement that extends their existing commercial relationship. This includes a purchase and supply commitment, as well as a pledge to share samples to advance cancer research.

"Both companies are deeply committed to our collaboration to help patients and conquer cancer," Guardant Chief Commercial Officer Chris Freeman said in a statement.

Monetary and other details of the companies' agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.